drugset
drugset / Trial / NCT02100930

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

NCT02100930 ↗

Completed 69 enrolled Memorial Sloan Kettering Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to be able to supply an experimental combination of drugs called 3F8 and GM-CSF (also called sargramostim) to patients with high-risk neuroblastoma who may benefit from treatment.

Timeline

Start
2014-03
Primary completion
2019-03-07
Completion
2019-03-07

Drugs

EvaluationDrugModalityDoseRoute
Subject 3F8 Monoclonal antibody — Intravenous
Subject Isotretinoin Other / unclassified — Oral
Subject sargramostim Protein / enzyme biologic — Subcutaneous

Indications

neuroblastoma